First studies underway at Mayday University Hospital!

Posted:
16
June 2005

We are delighted to have started conducting clinical trials within Mayday University Hospital's flagship facilities. Construction and development of the new purpose built units was completed in May, allowing Early Phase studies to commence and complement our other premises within St George's University London.

“We moved into our new premises in early May and we are now conducting clinical research within the Mayday units. The transition has been very smooth and we are already reaping the rewards of the enhanced set-up.”— Dr Jörg Täubel, Managing Director, Richmond Pharmacology.
“Running clinical trials in our Mayday unit is proving very advantageous. The additional capacity we can manage up to 100 in-patients simultaneously. Our facilities are designed specifically for client and panel requirements and this helps trial conduct to run efficiently. For example, we now have dedicated monitoring facilities on the ward, with adjoining offices for a variety of support functions. I'm looking forward to taking full advantage of these facilities.”— Jean Van Wyk, Senior Research Physician and Head of Medical Department.
“The facilities have been purpose built, and this provides a tremendous advantage for our volunteers. The wards and recreational areas are spacious and comfortable. Volunteer feedback on the internet and lounge rooms has been very favourable. And, of course, it's reassuring to work within the acute environment of the NHS Trust.”— Dr Ulrike Lorch, Medical Director.

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more